Keun Hur1, Yuji Toiyama1, Aaron J Schetter1, Yoshinaga Okugawa1, Curtis C Harris1, C Richard Boland1, Ajay Goel2. 1. Center for Gastrointestinal Research and Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, TX (KH, YT, YO, CRB, AG); National Cancer Institute, National Institutes of Health, Bethesda, MD (AJS, CCH). 2. Center for Gastrointestinal Research and Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, TX (KH, YT, YO, CRB, AG); National Cancer Institute, National Institutes of Health, Bethesda, MD (AJS, CCH). ajay.goel@baylorhealth.edu rickbo@baylorhealth.edu.
Abstract
BACKGROUND: Distant metastasis is the major cause of mortality in colorectal cancer (CRC). We performed a systemic, comprehensive discovery for expression patterns of metastasis-specific microRNAs (miRNAs) by directly comparing primary CRCs (pCRCs) and matched liver metastases (LMs) and evaluated the feasibility of their clinical application as metastasis-specific biomarkers. METHODS: CRC metastasis-specific miRNA profiles were generated by analyzing nine pairs of pCRC and LM tissues, followed by quantitative validation in an independent cohort of 58 pairs of matched pCRC and LM tissues. We evaluated associations between miRNA expression and patient survival and ability to predict metastasis in another 84 patients with CRC. Subsequently, associations were quantitatively validated in 175 CRC tissues and 169 serum samples. Kaplan-Meier, Cox regression, and logistic regression analyses were used. All statistical tests were two-sided. RESULTS: Twenty-three miRNAs were identified that were differentially expressed between pCRC and LM (P < .001; FDR < .5). Four miRNAs downregulated in LM (let-7i, miR-10b, miR-221, and miR-320a) and one upregulated miR (miR-885-5p) were quantitatively validated in pCRC (P < .0001). Low let-7i expression in pCRC tissue predicted worsened prognosis (hazard ratio [HR] = 5.0, 95% confidence interval [CI] = 1.0 to 24.4, P = .0479) as well as distant metastasis (odds ratio [OR] = 5.5, 95% CI = 1.1 to 26.8, P = .0334). High miR-10b expression in pCRC tissue independently predicted distant metastasis (OR = 4.9, 95% CI = 1.2 to 19.7, P = .0248). High serum miR-885-5p expression independently predicted prognosis (HR = 2.9, 95% CI = 1.1 to 7.5, P = .0323), LN metastasis (OR = 3.0, 95% CI = 1.3 to 7.2, P = .0116), and distant metastasis (OR = 3.1, 95% CI = 1.0 to 10.0, P = .0456), whereas tissue miR-885-5p expression did not. Expression patterns of miRNAs were confirmed by in situ hybridization. CONCLUSIONS: We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
BACKGROUND: Distant metastasis is the major cause of mortality in colorectal cancer (CRC). We performed a systemic, comprehensive discovery for expression patterns of metastasis-specific microRNAs (miRNAs) by directly comparing primary CRCs (pCRCs) and matched liver metastases (LMs) and evaluated the feasibility of their clinical application as metastasis-specific biomarkers. METHODS: CRC metastasis-specific miRNA profiles were generated by analyzing nine pairs of pCRC and LM tissues, followed by quantitative validation in an independent cohort of 58 pairs of matched pCRC and LM tissues. We evaluated associations between miRNA expression and patient survival and ability to predict metastasis in another 84 patients with CRC. Subsequently, associations were quantitatively validated in 175 CRC tissues and 169 serum samples. Kaplan-Meier, Cox regression, and logistic regression analyses were used. All statistical tests were two-sided. RESULTS: Twenty-three miRNAs were identified that were differentially expressed between pCRC and LM (P < .001; FDR < .5). Four miRNAs downregulated in LM (let-7i, miR-10b, miR-221, and miR-320a) and one upregulated miR (miR-885-5p) were quantitatively validated in pCRC (P < .0001). Low let-7i expression in pCRC tissue predicted worsened prognosis (hazard ratio [HR] = 5.0, 95% confidence interval [CI] = 1.0 to 24.4, P = .0479) as well as distant metastasis (odds ratio [OR] = 5.5, 95% CI = 1.1 to 26.8, P = .0334). High miR-10b expression in pCRC tissue independently predicted distant metastasis (OR = 4.9, 95% CI = 1.2 to 19.7, P = .0248). High serum miR-885-5p expression independently predicted prognosis (HR = 2.9, 95% CI = 1.1 to 7.5, P = .0323), LN metastasis (OR = 3.0, 95% CI = 1.3 to 7.2, P = .0116), and distant metastasis (OR = 3.1, 95% CI = 1.0 to 10.0, P = .0456), whereas tissue miR-885-5p expression did not. Expression patterns of miRNAs were confirmed by in situ hybridization. CONCLUSIONS: We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
Authors: Vlastimil Kulda; Martin Pesta; Ondrej Topolcan; Vaclav Liska; Vladislav Treska; Alan Sutnar; Karel Rupert; Marie Ludvikova; Vaclav Babuska; Lubos Holubec; Radim Cerny Journal: Cancer Genet Cytogenet Date: 2010-07-15
Authors: Munekazu Yamakuchi; Craig D Lotterman; Clare Bao; Ralph H Hruban; Baktiar Karim; Joshua T Mendell; David Huso; Charles J Lowenstein Journal: Proc Natl Acad Sci U S A Date: 2010-03-22 Impact factor: 11.205
Authors: Raffaele Baffa; Matteo Fassan; Stefano Volinia; Brian O'Hara; Chang-Gong Liu; Juan P Palazzo; Marina Gardiman; Massimo Rugge; Leonard G Gomella; Carlo M Croce; Anne Rosenberg Journal: J Pathol Date: 2009-10 Impact factor: 7.996
Authors: Jochen Gaedcke; Marian Grade; Jordi Camps; Rolf Søkilde; Bogumil Kaczkowski; Aaron J Schetter; Michael J Difilippantonio; Curtis C Harris; B Michael Ghadimi; Søren Møller; Tim Beissbarth; Thomas Ried; Thomas Litman Journal: Clin Cancer Res Date: 2012-07-31 Impact factor: 12.531
Authors: David A Armstrong; John A Dessaint; Carol S Ringelberg; Haley F Hazlett; Louisa Howard; Moemen A K Abdalla; Roxanna L Barnaby; Bruce A Stanton; Mark A Cervinski; Alix Ashare Journal: J Mol Diagn Date: 2018-06-22 Impact factor: 5.568